Redeye comments on Binero IT’s H1-25 results, which presented mixed figures.
Redeye is not surprised by the announced directed share issue of SEK6m.
Redeye comments on Binero Group's H1-25 results, which presented mixed figures.
Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-lin...
Redeye provides an update following Jumpgate’s Q1 2025 report.
Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase ...
Redeye comments on Dala Energi’s Q2 report, which was again characterised by the strategic restructu...
Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encou...
In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hosp...
The offering represents a 55% discount from yesterday's trading, and we find that Hargreaves has no ...
Redeye updates its estimates following Fable Media Group’s Q2 report, which came in largely in line ...
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det andra ...
Redeye notes that Systemair is posting solid Q1 numbers with some minor deviations to our estimates.
Redeye comments on the now confirmed partnering with industry giant Quest Diagnostics for channel co...
Redeye provides a research update following the Q2 report published by Lipum earlier today.
Redeye comments on Jumpgate’s Q2 report, which was broadly in line with our estimates, with the exce...
Redeye comments on MindArk’s Q2 results, which came in stronger than expected.
Redeye comments on Fable Media Group’s Q2 results, aligning with the preliminary figures and our est...
Double Bond Pharmaceutical utvecklar läkemedelskandidaten SI-053, för behandling av glioblastom, en ...
Redeye comments on GiG’s Q2-results which were in line with expectations and the preliminary outcome...